Teva submitted an unsolicited $40B expression of interest to acquire Mylan at $82 per share (cash and stock). Mylan's board unanimously rejected the proposal April 27, 2015. Teva withdrew its proposal July 27, 2015 to focus on the Allergan generics acquisition. Counted here as a publicly announced terminated deal.